Clinical trial
Open-Label Adalimumab for Ulcerative Colitis Patients
NCT00421642 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00421642 |
|---|---|
| Title | Open-Label Adalimumab for Ulcerative Colitis Patients |
| Official title | An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Ulcerative Colitis Patients |
| Lead sponsor | Mayo Clinic, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Adalimumab |
| Enrollment | 20 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jan 12, 2007 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: